U.S. Hemostats Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

U.S. Hemostats Market Size

• U.S. Hemostats market size was valued at USD 1.17 billion in 2024 and is expected to reach USD 2.06 billion by 2032, at a CAGR of 7.30% during the forecast period
• The market growth is primarily driven by the increasing number of surgical procedures and trauma cases across hospitals and ambulatory centers, boosting the demand for effective bleeding control solutions
• In addition, advancements in hemostatic agent formulations and the growing emphasis on minimally invasive surgeries are fostering broader adoption of hemostats. These evolving clinical needs and innovations are accelerating the market's expansion, positioning hemostats as a critical component in modern surgical care

U.S. Hemostats Market Analysis

• U.S. Hemostats, used to control bleeding during surgical procedures, are increasingly essential components of modern surgical practice in the U.S. due to their ability to minimize blood loss, enhance surgical precision, and improve patient outcomes across a range of specialties
• The escalating demand for hemostats is primarily fueled by the rising number of surgical interventions, growing prevalence of chronic diseases, and an increasing shift toward minimally invasive procedures that require effective and rapid hemostatic solutions
• The U.S. hemostats market is also experiencing growth due to continued innovation by medical device companies, a well-established healthcare infrastructure, and the expanding use of hemostatic agents in outpatient and emergency care settings
• Absorbable hemostats are increasingly preferred in cardiovascular surgeries due to their biocompatibility and ability to perform effectively in confined surgical fields without the need for removal
• Cardiovascular surgery dominated the U.S. hemostats market with a revenue share of 32.1% in 2024, driven by the high incidence of heart-related conditions and the critical need for precise bleeding control during complex surgical procedures

Report Scope and U.S. Hemostats Market Segmentation      

U.S. Hemostats Market Trends

“Innovation in Absorbable Hemostats for Minimally Invasive Surgeries”

• A significant and accelerating trend in the U.S. hemostats market is the innovation in absorbable hemostatic agents tailored for minimally invasive and complex surgeries. These products are designed to provide rapid hemostasis, reduce the need for removal, and integrate seamlessly with advanced surgical techniques
• For instance, Ethicon’s SURGICEL® Powder, an oxidized regenerated cellulose-based absorbable hemostat, is specifically designed to address challenging bleeding scenarios in laparoscopic procedures by conforming to irregular wound surfaces
• Recent product advancements include enhanced delivery systems such as pre-loaded applicators for laparoscopic use, enabling better access to confined surgical areas while maintaining sterility and ease of application. These tools support improved workflow efficiency and reduce operating time in complex procedures
• The rise in cardiovascular, neurological, and orthopedic surgeries requiring precise bleeding control has increased demand for specialized absorbable hemostats that support minimally invasive approaches. For instance, Baxter’s TISSEEL fibrin sealant continues to be widely used due to its strong clotting performance in difficult-to-reach bleeding sites
• Hospitals and surgical centers are increasingly adopting these advanced solutions as part of enhanced recovery protocols and infection control strategies. The demand is particularly high among surgeons aiming for reduced complications and shorter patient recovery times
• This trend is reshaping clinical expectations, with healthcare providers and surgeons favoring next-generation hemostats that combine high efficacy, biocompatibility, and procedural efficiency in a minimally invasive surgical environment

U.S. Hemostats Market Dynamics

Driver

“Surging Surgical Volumes and Demand for Efficient Blood Management”

• The growing number of surgical procedures in the U.S., driven by an aging population and increasing prevalence of chronic diseases, is a major factor contributing to the rising demand for effective hemostatic agents
• For instance, the Centers for Medicare & Medicaid Services (CMS) continues to report high volumes of cardiovascular and orthopedic surgeries, which require precise bleeding control to improve outcomes and reduce post-operative complications
• Hemostats provide critical support by minimizing intraoperative bleeding, which is vital in reducing transfusion requirements and improving surgical field visibility. Their ability to shorten procedure time and promote faster recovery has made them a staple in modern operating rooms
• In addition, with the growing adoption of minimally invasive and outpatient procedures, demand for fast-acting, absorbable hemostats has surged. These are particularly valuable in ambulatory surgical centers (ASCs), where efficiency and safety are top priorities
• The increased focus on hospital cost-efficiency, patient safety, and surgical excellence is driving healthcare providers to adopt advanced hemostatic technologies that support better clinical outcomes and align with value-based care initiatives

Restraint/Challenge

“Stringent Regulatory Approvals and Product Safety Concerns”

• The stringent U.S. FDA regulatory approval process for surgical hemostats, especially those containing biologically derived components, poses a key barrier for market entry and expansion of new products
• For instance, collagen- and thrombin-based hemostats often undergo extended review timelines due to potential risks such as allergic reactions, delayed absorption, or adverse immune responses, requiring robust clinical validation and post-market surveillance
• Concerns over product safety, biocompatibility, and long-term tissue integration are heightened in surgeries involving sensitive organs or high-risk patients, leading some clinicians to prefer established hemostatic brands with long-term clinical data
• Furthermore, product recalls due to contamination risks or performance inconsistencies can hinder market growth and erode brand trust. Companies must invest significantly in quality assurance, regulatory compliance, and clinician training to meet these expectations
• Addressing these challenges through investment in R&D, stronger clinical trials, and streamlined regulatory strategies will be essential for sustained growth and innovation in the U.S. hemostats market

U.S. Hemostats Market Scope

The market is segmented on the basis of type, formulation, application, indication, distribution channel, and end users.

• By Type

On the basis of type, the U.S. hemostats market is segmented into combination agent hemostats, thrombin-based hemostats, collagen-based hemostats, oxidized regenerated cellulose (ORC)-based hemostats, and gelatine-based hemostats. The combination agent hemostats segment held the largest market revenue share in 2024 due to its superior hemostatic efficacy through the synergistic effect of multiple components such as thrombin and collagen. These products are widely adopted in surgeries involving complex bleeding due to their rapid action and strong adherence to tissue surfaces. Surgeons prefer them in critical cases where time and efficiency are essential, especially in cardiovascular and liver procedures.

The thrombin-based hemostats segment is expected to witness the fastest growth rate from 2025 to 2032, driven by their versatility, rapid clot-inducing properties, and wide usage across various surgical specialties. These agents are particularly effective in minimally invasive surgeries, and recent innovations in recombinant thrombin production are enhancing their safety and acceptance.

• By Formulation

On the basis of formulation, the U.S. hemostats market is categorized into matrix and gel hemostats, sheet and pad hemostats, sponge hemostats, and powder hemostats. The matrix and gel hemostats segment dominated the market in 2024 due to their ability to conform to irregular wound sites and their effectiveness in achieving localized hemostasis in minimally invasive procedures. These are particularly favored in laparoscopic and neurosurgeries.

The powder hemostats segment is anticipated to grow at the highest CAGR during the forecast period, owing to their ease of application, minimal preparation time, and effectiveness in controlling diffuse bleeding over large surface areas.

• By Application

On the basis of application, the U.S. hemostats market includes orthopedic, general surgery, neurological surgery, cardiovascular surgery, reconstructive surgery, and gynecological surgery. Cardiovascular surgery held the largest market share of 32.1% in 2024, driven by the high frequency of procedures and critical need for effective hemostasis during complex heart operations.

Orthopedic surgery is expected to witness the fastest CAGR from 2025 to 2032, due to the increasing incidence of joint replacement and spinal procedures, where hemostats play a crucial role in reducing intraoperative blood loss.

• By Indication

On the basis of indication, the U.S. hemostats market is segmented into surgical hemostats and wound closure. The surgical hemostats segment led the market in 2024 due to its broad application across a variety of operative settings, particularly in hospital operating rooms and ambulatory surgical centers. These products are vital in enhancing visibility and reducing transfusion needs.

The wound closure segment is expected to witness the fastest CAGR from 2025 to 2032, as demand increases in trauma care, emergency medicine, and military applications where rapid bleeding control is necessary.

• By Distribution Channel

On the basis of distribution channel, the U.S. hemostats market is divided into direct tender and third-party distributors. The direct tender segment accounted for the majority market share in 2024, as hospitals and large healthcare networks often procure hemostatic agents through bulk purchasing agreements with manufacturers.

However, third-party distributors is expected to witness the fastest CAGR from 2025 to 2032, especially in outpatient and smaller clinical settings that rely on localized purchasing.

• By End Users

On the basis of end users, the U.S. hemostats market is segmented into hospitals, ambulatory surgical centers, community healthcare, clinics, and others. Hospitals dominated the market with the largest revenue share in 2024, owing to high surgical volumes, advanced facilities, and a strong presence of trained professionals.

Ambulatory surgical centers (ASCs) are expected to grow at the fastest pace during forecast period, due to the increasing shift toward outpatient surgical care, cost-efficiency, and rising use of minimally invasive techniques that demand effective and fast-acting hemostatic solutions.

U.S. Hemostats Market Share

The U.S. Hemostats industry is primarily led by well-established companies, including:

• Baxter International Inc. (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• Teleflex Incorporated (U.S.)
• Pfizer Inc. (U.S.)
• Medtronic (Ireland)
• B. Braun SE (Germany)
• Stryker (U.S.)
• Zimmer Biome (U.S.)
• CryoLife, Inc. (U.S.)
• Integra LifeSciences Corporation (U.S.)
• BD (U.S.)
• 3-D Matrix, Ltd. (Japan)
• Hemostasis LLC (U.S.)
• Advance Medical Solutions Group plc (U.K.)
• Biocer Entwicklungs-GmbH (Germany)
• Biom'Up SA (France)
• Genesis BPS (U.S.)
• Marine Polymer Technologies, Inc. (U.S.)

What are the Recent Developments in U.S. Hemostats Market?

• In April 2023, Baxter International Inc. announced the U.S. launch of its next-generation Floseal Hemostatic Matrix, designed to provide more rapid and reliable bleeding control in complex surgical procedures. The updated formulation offers enhanced viscosity and delivery precision, enabling surgeons to apply the product more efficiently in minimally invasive environments. This development reinforces Baxter’s leadership in surgical hemostasis and highlights the growing demand for advanced, easy-to-use solutions in high-pressure surgical settings
• In March 2023, Ethicon, a Johnson & Johnson MedTech company, expanded its SURGICEL® Powder product line in the U.S. with an advanced applicator designed for laparoscopic and robotic-assisted surgeries. The innovation addresses the challenges of accessing bleeding sites in minimally invasive procedures and demonstrates Ethicon’s commitment to supporting evolving surgical techniques with adaptable and effective hemostatic solutions
• In February 2023, Teleflex Incorporated introduced its Hem-o-lok Polymer Ligation System upgrade in U.S. surgical centers, emphasizing improved control and enhanced visualization for vascular ligation in minimally invasive surgeries. This advancement aims to optimize intraoperative workflow while maintaining a high standard of hemostasis. The product’s U.S. rollout underlines Teleflex’s continued focus on procedural safety and surgeon convenience
• In January 2023, Medcura Inc., in collaboration with the U.S. Department of Defense, announced clinical development progress on its next-generation hemostatic gel, targeting battlefield trauma and emergency surgical applications. The gel formulation, which rapidly stops bleeding without relying on clotting factors, is part of a broader strategy to develop hemostats suited for both civilian and military environments. This highlights a rising trend in dual-use hemostatic innovations aimed at high-risk scenarios
• In January 2023, Z-Medica LLC (a part of Teleflex) reported increased adoption of its QuikClot® Combat Gauze® by emergency departments and trauma centers across the U.S., driven by its proven efficacy in critical bleeding control. Originally developed for military use, the gauze is now widely implemented in civilian trauma care, emphasizing the growing crossover between military-grade hemostatic solutions and advanced hospital-based applications

SKU-66350